Advanced or metastatic KRAS-mutant tumor in pancreatic adenocarcinoma

Clinical trials for Advanced or metastatic KRAS-mutant tumor in pancreatic adenocarcinoma explained in plain language.

Never miss a new study

Get alerted when new Advanced or metastatic KRAS-mutant tumor in pancreatic adenocarcinoma trials appear

Sign up with your email to follow new studies for Advanced or metastatic KRAS-mutant tumor in pancreatic adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug targets hard-to-treat KRAS cancers in early trial

Disease control Recruiting now

This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and how well it shrinks tumors. About 110 adults who have already tried standard t…

Matched conditions: ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN PANCREATIC ADENOCARCINOMA

Phase 1/2 • Sponsor: Auricula Biosciences Inc. • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

Advanced or metastatic KRAS-mutant tumor in pancreatic adenocarcinoma

Get alerted when new Advanced or metastatic KRAS-mutant tumor in pancreatic adenocarcinoma trials appear

New drug targets hard-to-treat KRAS cancers in early trial